Option Care Health, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Option Care Health provides infusion therapy and related services through a national network of pharmacies and ambulatory infusion suites; it reports as one operating segment.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $1,069.1 million | $980.8 million | $2,084.9 million | $1,896.6 million |
| Gross profit / margin | $250.8 million / 23.5% | $216.9 million / 22.1% | $479.8 million / 23.0% | $417.8 million / 22.0% |
| Operating income / margin | $82.4 million / 7.7% | $59.1 million / 6.0% | $149.0 million / 7.1% | $111.3 million / 5.9% |
| Net income | $114.4 million | $33.9 million | $153.6 million | $64.2 million |
| Diluted EPS | $0.63 | $0.19 | $0.84 | $0.35 |
- Q2 revenue grew 9.0%; first-half revenue grew 9.9%. Management attributed growth principally to organic therapy growth: chronic therapies grew at a low-double-digit rate and acute therapies at a mid-single-digit rate. Divestitures of respiratory assets and ALS and pre-term-labor therapies partially offset growth.
- Gross margin improved year over year, which management attributed to disciplined procurement, favorable therapy pricing, efficient infusion-suite utilization, and lessening inflationary pressure. Q2 SG&A increased 8.3% but declined slightly as a share of revenue, to 14.4% from 14.5%.
- First-half operating cash flow was $259.3 million, versus $137.0 million; investing cash outflow was $26.4 million, versus $70.0 million; financing cash outflow was $85.9 million, versus $17.6 million. Cash increased to $441.2 million from $294.2 million at year-end.
- At June 30, cash was $441.2 million and debt principal was $1.091 billion (net carrying value $1.063 billion). Net debt using principal less cash was approximately $649.8 million. The company had $219.5 million of net availability under its ABL facility, after outstanding letters of credit.
- First-lien term-loan interest was 7.90% at quarter-end, up from 6.82% at December 31, 2022; senior notes bear interest at 4.375%. The first-lien loan and ABL reference rates were amended from LIBOR to SOFR. The company paid $34.0 million of cash interest in the first half.
Material changes and unusual items
- The proposed Amedisys merger was terminated by mutual agreement on June 26, 2023. Option Care received a $106.0 million termination payment. Q2 other, net included this payment and $21.1 million of merger-related expenses; the resulting $84.9 million pre-tax amount drove reported other income. The company disclosed that $62.8 million of first-half net income related to the termination payment, net of merger expenses and taxes. Reported earnings therefore include a material nonrecurring benefit.
- Revenue growth and improved gross margin supported higher operating income. Net income growth was also substantially affected by the Amedisys termination payment, so reported earnings growth is not solely attributable to recurring operations.
- The company acquired Revitalized, LLC in May for $12.9 million, net of cash acquired. It also repurchased $75.0 million of stock in March at an average $30.30 per share; up to $175.0 million remained authorized at June 30.
Outlook, risks and contingencies
- No specific financial guidance was provided in the supplied filing text. Management said existing cash, expected operating cash flows, and planned capital spending should be sufficient for operating requirements over the next 12 months and beyond; additional funding may be needed for longer-term plans or acquisitions.
- Risks include reimbursement estimates and changing payer rules, significant supplier concentration (four vendors accounted for about 74% of first-half pharmaceutical and medical-supply purchases), and variable-rate debt exposure. The largest payer represented about 14% of revenue; direct government programs accounted for about 12%.
- The company described routine legal proceedings, audits, and investigations, but said it did not expect pending matters, after reserves and indemnification, to materially affect its balance sheet. It cautioned that unexpected judgments, fines, or settlements could affect results or cash flows.
- Management noted that new COVID-19 variants could affect operations, but it could not confidently forecast the duration or financial impact. No material changes to previously disclosed risk factors or market-risk exposure were reported.
Investor verification points
- Assess recurring performance separately from the Amedisys termination benefit and related expenses when evaluating earnings and operating cash flow.
- Track whether gross-margin improvement, organic therapy growth, and operating expense leverage persist.
- Monitor term-loan interest costs, SOFR exposure, debt repayment, and liquidity available for acquisitions and capital returns.
- Review payer reimbursement estimates, supplier concentration, and developments in legal or regulatory matters.